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Abstract
Background: Elimination of onchocerciasis (river blindness) through mass administration of ivermectin in the six countries
in Latin America where it is endemic is considered feasible due to the relatively small size and geographic isolation of
endemic foci. We evaluated whether transmission of onchocerciasis has been interrupted in the endemic focus of Escuintla-
Guatemala in Guatemala, based on World Health Organization criteria for the certification of elimination of onchocerciasis.
Methodology/Principal Findings: We conducted evaluations of ocular morbidity and past exposure to Onchocerca volvulus
in the human population, while potential vectors (Simulium ochraceum) were captured and tested for O. volvulus DNA; all of
the evaluations were carried out in potentially endemic communities (PEC; those with a history of actual or suspected
transmission or those currently under semiannual mass treatment with ivermectin) within the focus. The prevalence of
microfilariae in the anterior segment of the eye in 329 individuals ($7 years old, resident in the PEC for at least 5 years) was
0% (one-sided 95% confidence interval [CI] 0–0.9%). The prevalence of antibodies to a recombinant O. volvulus antigen (Ov-
16) in 6,432 school children (aged 6 to 12 years old) was 0% (one-sided 95% IC 0–0.05%). Out of a total of 14,099 S.
ochraceum tested for O. volvulus DNA, none was positive (95% CI 0–0.01%). The seasonal transmission potential was,
therefore, 0 infective stage larvae per person per season.
Conclusions/Significance: Based on these evaluations, transmission of onchocerciasis in the Escuintla-Guatemala focus has
been successfully interrupted. Although this is the second onchocerciasis focus in Latin America to have demonstrated
interruption of transmission, it is the first focus with a well-documented history of intense transmission to have eliminated
O. volvulus.
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Introduction
Onchocerciasis (river blindness) is caused by a filarial nematode
transmitted by black flies of the genus Simulium [1]. The disease
may be mild (dermatitis) or severe (visual impairment and
blindness) and is caused by the human immune response to
microfilariae (mf) released by female adult worms as they move
across subcutaneous tissue and spread throughout the body.
Humans are the only known reservoir [2].
Onchocerciasis occurs throughout much of East and West Africa
and Yemen, and was brought to the Americas through the slave
trade [3]. It is now endemic to 6 countries in Latin America (Brazil,
Colombia, Ecuador, Guatemala, Mexico and Venezuela). Foci of
transmission in the Americas are relatively small and geographically
delimited compared to areas of transmission in Africa [4]. In part
due to the geographical isolation of foci, the goal of the
Onchocerciasis Elimination Program of the Americas (OEPA) is
both to eliminate ocular morbidity throughout the region, and to
permanently interrupt transmission where possible [1,5].
Control and eventual regional elimination of transmission is
considered feasible due to the efficacy of ivermectin (MectizanH,
donated by Merck&Co, Inc.) as a microfilaricide, when used twice
per year [6,7]. While ivermectin used in this manner prevents
transmission of infections, it does not kill adult worms [8] although
it may reduce their fecundity and lifespan [9]. OEPA, along with
its ministry of health counterparts, supports mass treatment with
ivermectin twice per year, with the goal of reaching 85% of eligible
individuals (those $5 years of age, $90 cm of height and $15 kg
of weight; excluded are pregnant women and individuals with
severe disease) living in endemic areas. Recent reanalysis of
information on the effectiveness of ivermectin delivered in this
strategy has suggested that six and a half years (13 treatment
www.plosntds.org 1 March 2009 | Volume 3 | Issue 3 | e404rounds) of such coverage can be sufficient to interrupt transmission
[7].
Guatemala, with a population eligible for treatment of 175,881
(to receive 351,762 treatments) in 2006 [5] accounts for 38.5% of
the endemic population eligible for treatment in Latin America.
Guatemala has four endemic foci: Santa Rosa (Department of
Santa Rosa), Huehuetenango (Department of Huehuetenango),
Escuintla-Guatemala (Departments of Escuintla and Guatemala)
and the Central Endemic Zone (Departments of Suchitepe ´quez,
Solola ´ and Chimaltenango; Figure 1) [10]. The Guatemalan
Ministry of Public Health and Social Welfare (MSPAS, in its
Spanish acronym) has been delivering ivermectin to endemic
communities, through mass drug administration (MDA), since
1988 [8] and has reached 85% of the eligible population at risk
twice per year in all foci since 2001 (Figure 2) [5].
Beginning in 2004, the MSPAS, in partnership with OEPA, the
US Centers for Disease Control and Prevention (CDC) and the
Universidad del Valle de Guatemala (UVG), began evaluating
three of the four endemic foci in the country to determine whether
transmission had been interrupted in these areas and if semiannual
treatment could be suspended. Criteria for making these
determinations are based on World Health Organization
(WHO) guidelines presented in the 2001 document ‘‘Certification
of Elimination of Human Onchocerciasis: Criteria and Proce-
dures’’ [11] as adapted for field conditions by Lindblade et al. [12]
and the OEPA steering committee (the Program Coordinating
Committee-PCC) [1]. In summary, the criteria to be applied in
areas with historically documented onchocerciasis transmission
include: 1) demonstration of a prevalence of mf in the anterior
segment (MfAS) of the eye (anterior chamber and cornea) to be
less than 1%; 2) a cumulative incidence of O. volvulus infection of
less than 0.1% in school-age children; and 3) a prevalence of
infection in vectors of less than 0.05% [11,13]. Based on these
criteria, Lindblade et al. demonstrated that transmission had been
interrupted in the Santa Rosa focus; [12] subsequently, the PCC
recommended to the Minister of Public Health of Guatemala that
treatment be suspended in this focus. That recommendation was
accepted and the Santa Rosa focus is currently under a three year
post treatment surveillance phase to monitor for transmission
recrudescence [5].
In this report, we evaluate the current status of transmission of
O. volvulus in the Escuintla-Guatemala focus based on the adapted
WHO criteria.
Methods
The Escuintla-Guatemala focus
In 2007, the Escuintla-Guatemala focus consisted of 49,616
individuals at risk, with 45,224 eligible for treatment, divided
among 103 communities in the department of Escuintla (14.30uN,
90.79uW), and 14 communities in the department of Guatemala
(14.62uN, 90.53uW). Historically, this focus included areas with
intense transmission: between 1979–1982, the community mf
prevalence ranged from 8 to 38%. [14] A larval control effort from
1979–1989 significantly reduced both biting density and commu-
nity mf prevalence.
Potentially endemic communities (PEC)
To ensure that all areas with current or past evidence of
onchocerciasis transmission were included in this evaluation, all
communities with at least one of the following characteristics were
identified using historical data, including unpublished reports from
the MSPAS and published articles: a) past evidence of onchocer-
ciasis transmission (nodules or mf in at least one community
resident); b) suspicion of past transmission suggested by a
documented survey, which may not have found evidence of
transmission; or c) currently under semiannual ivermectin
treatment by the MSPAS. A total of 155 communities satisfied
at least one of these criteria) (Figure 3). These potentially endemic
communities (PEC) served as the sampling frame for all
evaluations of the status of transmission of onchocerciasis
(Figure 3).
Ophthalmologic evaluation
Because ocular morbidity is more likely to be found where
onchocerciasis transmission is most intense, [15] we evaluated
ocular lesions associated with onchocerciasis only in communities
that historically had the highest rates of transmission. PEC with
.0% nodule prevalence in the last 3 MSPAS surveys (1989, 1990
and 1991) and elevation .800 m were considered in order to
maximize the possibility of finding O. volvulus related morbidity. A
total of 16 communities satisfied these criteria. Two of these
communities were dropped before the evaluation began because
they had less than 5 inhabitants, and one was not included because
it effectively serves as a bedroom community for Guatemala City,
making it very difficult to locate potential participants in their
homes.
The calculation of minimum sample size was based on
estimating a population prevalence of MfAS of the eye of less
than 1%. Finding 0 positive individuals out of 300 examined will
allow a one-sided 95% confidence interval (CI) to exclude 1%.
Given an estimated non-response rate of 10%, the total sample
size required was 330.
All houses of the selected communities were mapped and the
residents were censused using a pre-programmed hand-held
personal digital assistant (PDA) with a global positioning system
(GPS) attached. Eligible residents (those who were $7 years old
and who had resided in the community for at least the last 5 years)
were identified and recorded. As the ophthalmologist is capable of
evaluating up to 90 individuals per day, we stratified communities
Author Summary
Brought to the Americas from Africa by the slave trade,
onchocerciasis is present in six countries in Latin America.
The disease is caused by a round worm and is transmitted
to humans by the bite of an infected black fly. Once in a
human, the adult worms produce larvae that circulate
through the body, causing itching or even blindness.
Ivermectin, a drug that kills the larvae, is delivered by
public health authorities in countries where the disease is
present. If the larvae are killed, then the disease cannot be
transmitted to more people. People living in the Escuintla-
Guatemala focus, a region in Guatemala where the disease
was common, have been taking ivermectin for many years.
The Ministry of Health of Guatemala believes that
onchocerciasis is no longer being transmitted in the area.
To prove that there is no more transmission of the disease,
the authors examined the eyes of residents of the area to
see if they could find any evidence of the worms. They also
conducted analyses of blood in school children to see if
they had ever been exposed to the worm, and they caught
thousands of black flies and tested them to see if they
were infected. These evaluations found no evidence of
transmission of the disease in the Escuintla-Guatemala
focus. As a result, local public health authorities can stop
giving ivermectin and invest their human resources in
other important diseases.
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residents. In the small communities (,90 residents), all eligible
individuals (N,266) were invited to participate. In the larger
communities ($90 residents), a PDA-based algorithm was applied
in the field to randomly select 12% of the households and their
members for inclusion in the evaluation (N,223).
Figure 1. The four onchocerciasis foci in Guatemala (dark gray) in the endemic departments (light gray).
doi:10.1371/journal.pntd.0000404.g001
Figure 2. Ivermectin biannual treatment coverage from 1996 to 2007 in the Escuintla-Guatemala focus.
doi:10.1371/journal.pntd.0000404.g002
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evaluations of onchocerciasis-related eye disease performed the
ophthalmologic evaluations. Visual acuity was measured with a
Snellen chart using standard methods. Ocular examinations were
conducted with a split-lamp in a darkened area after the patients
were asked to sit with their head between their legs for 5 minutes
[16]. MfAS were noted as live/coiled or dead/straightened. Data
were entered in the PDA and later downloaded to a database for
subsequent analysis.
Serologic evaluation
We estimated the cumulative incidence of O. volvulus infection
by measuring the prevalence of antibodies (IgG4) to a
recombinant antigen of O. volvulus, OV-16, [17] in a stratified
sample of school children 6–12 years old. We chose to stratify the
sample into urban and rural schools because it was possible that
levels of transmission would differ significantly between industri-
alized urban areas and rural communities located close to black
fly breeding sites. The urban areas were taken to be the 2 large
cities in the focus (San Vicente Pacaya and Palı ´n), and the
remainder of the schools located outside these cities were
considered to be rural.
Information about schools and the number of children aged 6
through 12 who were attending was obtained with the help of the
MSPAS and the Ministry of Education. Based on these figures, we
estimated 4,674 eligible children in the urban schools and 9,815 in
the rural schools. Schools were ordered at random within each
stratum and then selected until the target sample size had been
reached. The selected schools were visited and meetings were held
with directors, teachers and parents to explain the evaluation.
Teachers were asked to prepare a list of all enrolled children for
the day of the evaluation.
Based on the WHO certification for elimination criteria
(cumulative incidence ,0.1%) and considering antibody preva-
lence equivalent to the cumulative incidence rate, 3,000 children
were required in each stratum to calculate a one-sided 95% CI
that excluded 0.1% when no seropositives were encountered.
Given an expected 30% non-response rate, our target sample size
was 4,286 in each stratum.
The methods used to collect finger-prick blood samples and
data on residency from children participating in the evaluation
have been described previously [12]. Briefly, each participant
provided 80–120 uL of blood by standard sterile finger prick
procedures. Whatman filter paper No. 2 was used to collect the
Figure 3. Potentially endemic communities and sites for the entomologic, ophthalmologic and serologic evaluations in the
Escuintla-Guatemala focus.
doi:10.1371/journal.pntd.0000404.g003
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school on the appointed day were traced to their homes and asked
to participate. Blood samples were processed within two months of
collection using a standard ELISA [12].
Entomologic evaluation
Simulium flies were collected from November 2005 to April 2006
(peak biting season) in seven PEC and tested for infectivity in order
to calculate the Seasonal Transmission Potential (infected stage
larvae per person per season, STP). Collection sites were selected
through a rapid assessment of PEC to find those that satisfied the
following criteria: a) high densities of S. ochraceum; b) presence of
appropriate collection sites that capture areas where residents are
most likely to be exposed to vectors (i.e. casco, near a house and
cafetal, near coffee plantations); and c) willingness of the owner (in
the case of fincas [plantations]) or residents to participate.
We used similar methods described by Lindblade et al. [12].
Two teams of two people (collector and paid attractant, a male
resident of the finca $18 years old) rotated between two collection
sites (cafetal and casco) in each PEC. The paid attractants were given
ivermectin before starting collections and had finger-prick blood
samples taken on filter paper at the beginning and at the end of the
evaluation to evaluate exposure to O. volvulus. Collections started at
8:00 AM and ended at 5:00 PM taking 10 minute breaks at the
end of every hour and a 1 hour break at noon. Each community
was sampled two days per month.
At the laboratory at the UVG, the heads and thoraces of S.
ochraceum were separated from their bodies and up to 50 flies were
pooled per tube, maintaining separate months and communities.
The bodies were analyzed first using a standard polymerase chain
reaction (PCR) assay to detect O. volvulus DNA [18]. Positives were
confirmed by a second PCR. If a positive was confirmed, all the fly
heads of that community were tested.
Statistical methods
The one-sided 95% confidence intervals for the prevalence of
MfAS and antibodies to Ov16 were calculated using the SAS
(version 9.0, SAS Institute, Cary NC) FREQ procedure with the
EXACT statement, BINOMIAL option and an alpha level of
0.10. The Poolscreen 2.0 program was used to calculate the
proportion of infective flies based on the number of positive pools
[19]. Biting rates and STP were calculated according to standard
methods [12].
Ethics
All protocols received appropriate review and approval by the
CDC (Atlanta, GA), the ethics committee of the UVG (Guatemala
City, Guatemala), and the MSPAS (Guatemala City, Guatemala).
All participants $18 years of age or the parents or guardians of
children ,18 years old read or had read to them an informed
consent form and then were asked to sign or mark with their finger
to indicate their consent to participate. Children aged 7 to
,18 years old were read or had read to them an assent form and
asked to sign or mark with their fingerprint to indicate their
willingness to participate. Paid attractants also read or had read to
them a consent form and indicated their willingness to participate
with their signature or fingerprint.
Results
Ophthalmologic evaluation
Of the 13 communities selected for the evaluation, one could
not be reached due to road and weather conditions, and the only
family in a second community could not be found on the day of
the evaluation. We evaluated 329 (73.1%) of the 450 eligible
residents selected for inclusion in the evaluation. Of the total
evaluated, 55% were women and 36% were 7–15 years old.
Blindness due to onchocerciasis was not observed in any of the
patients and 306 (93%) individuals evaluated had their visual
acuity measured in the range of 20/20–20/70. No MfAS were
found; the prevalence of MfAS was therefore 0, with a one-sided
95% CI of 0–0.9%.
Serologic evaluation
In the urban area, we registered 4,674 enrolled children in 24
local schools, and 3,130 (67%) participated in the evaluation. Due
to an insufficient blood sample, the results for seven children could
not be determined. Out of the 3,123 samples analyzed, there was 1
positive (a 9 year old male living in an urban area) for antibodies
against O. volvulus. A second blood sample was requested and also
tested positive. The sample was sent for additional testing at an
experienced onchocerciasis laboratory in Mexico (Instituto
Polite ´cnico Nacional, Reynosa, Mexico) against recombinant
antigens Ov10, Ov11 and Ov16; the sample did not test positive
for any of these antigens and we therefore concluded that it was a
false positive and have recorded it as a negative result. In the rural
area, we registered 4,614 enrolled children in 34 schools, and
3,316 (72%) participated in the evaluation. A total of seven
samples again had to be discarded due to insufficient sample.
None of the 3,309 samples tested were positive for OV-16.
Therefore, the prevalence of antibodies to Ov16 in the Escuintla-
Guatemala focus was 0, and the one sided 95% IC was 0–0.05%.
Entomologic evaluation
A total of 28,423 Simulium flies were caught in 1,320 hours of
sampling, from November 2006 through April 2007. None of the
human attractants was found to be seropostitive for OV-16 either
before or after the evaluation. Of the flies collected, 17,336 (61%)
were S. ochraceum and 11,087 (39%) were S. metallicum (not
considered to be a vector of onchocerciasis when community mf
prevalence is low [20]). The highest biting densities were measured
in November and December. A total of 14,099 S. ochraceum in 303
pools were tested for O. volvulus DNA by PCR; all pools were
negative, thus, prevalence was 0% and the 95% CI was 0–0.01%.
The geometric mean biting rate for S. ochraceum was 11.0 bites/
person/hour while the arithmetic mean daily biting rate flies was
177 bites/person/day. As the proportion of infective flies was 0,
the STP was also 0. To calculate the maximum potential STP, we
used the upper end of the 95% CI of the proportion infective and
the geometric mean biting rate to calculate the maximum STP,
assuming that each infective fly would have 1 infective-stage larva.
The calculated maximum potential STP was 1.0 infective stage
larvae transmitted per person per season.
Discussion
Our findings, based on the ophthalmologic, entomologic and
serologic evaluations adapted from the WHO guidelines for
certification of elimination, indicate that transmission of O. volvulus
has been successfully interrupted in the Escuintla-Guatemala
focus. Our studies in this formerly endemic area demonstrated that
the prevalence of mf in the anterior segment of the eye was less
than 1%, evidence of active or prior infection (or exposure) as
measured by antibodies to a recombinant O. volvulus antigen (Ov-
16) in school children was less than 0.1%, and O. volvulus DNA in
vectors was under 0.05% (with a STP of 0 infective stage larvae
per person per season).
Interruption of O. volvulus Transmission
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extensively documented from 1979 to 1984 by the Guatemala-
Japan Cooperative Project on Onchocerciasis Research and
Control, which conducted a large-scale larval elimination program
in the area around the town of San Vicente Pacaya in the
Department of Escuintla [21]. Several communities in that area
had a prevalence of mf in the skin of 8% to 38% as recently as
1982 [14]. Nevertheless, community mf prevalence dropped from
an average of 26% to 7% during the years of the larval elimination
program [14]. Larval control efforts ceased in 1989, and a MSPAS
survey in1991 found community mf rates of 3% (MSPAS,
unpublished data; Figure 4). No surveys had been conducted in
Escuintla until the current report. However, the MSPAS provided
semiannual ivermectin treatments in the focus, reaching more
than 85% of the eligible population at risk twice per year from
2002 to 2007 (Figure 2).
Santa Rosa was the first focus in the Americas to demonstrate
interruption of onchocerciasis transmission, but there is evidence
that transmission was extremely low to nonexistent prior to
ivermectin distribution [5]. In contrast, levels of transmission in
the Escuintla-Guatemala focus were historically higher than the
Santa Rosa focus and transmission was well documented until at
least the early 1980s. The larviciding efforts in the San Vicente
Pacaya area from 1983–1989 were responsible for a significant
decline in vector biting rates and, subsequently, community mf
prevalence. The successful interruption of transmission after 12–13
rounds of MDA with ivermectin in San Vicente Pacaya may be at
least partially due to the reduction in mf prevalence resulting from
the larviciding campaign. While other areas of the Escuintla-
Guatemala focus experienced a decline in mf prevalence without
vector control, larviciding may be considered a complementary
strategy to mass drug administration in areas of intense
transmission.
Although the reported specificity of the Ov-16 ELISA test is
90%, [17] our laboratory has now tested over 9,964 samples from
endemic areas with only 1 false positive, a specificity of 99.99%.
However, distinguishing false from true positives is challenging.
We undertook extensive interviews of the family of the child
initially found positive to rule out travel to other endemic areas or
potential exposure to vectors during his daily activities. We tested
other family members, including a grandfather who reported a
nodule that was extirpated in the past, and none was found
positive. After a second blood sample from the same child tested
positive, we sent the samples for testing in another laboratory
against additional antigens, where the child’s samples were
negative in all external tests. We, therefore, feel confident
reporting this finding as a false positive.
The data presented in this report were extensively reviewed by
OEPA and the PCC. Based on the results, the PCC recommended
to the Minister of Health of Guatemala that ivermectin treatments
be suspended in the Escuintla-Guatemala focus in 2008. The
recommendation was accepted, and, as in Santa Rosa, three years
of surveillance for recrudescence has now begun during which a
final set of evaluations to ensure that transmission has been
completely eliminated will be undertaken [5].
Currently we are conducting a similar series of evaluations in
the focus of Huehuetenango along the border with Chiapas,
Mexico, to determine whether transmission has been interrupted
there. Results from these studies are expected mid-2008. As of the
writing of this article, transmission of O. volvulus continues in the
Central Endemic zone of Guatemala [5].
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Figure 4. Mean community prevalence of microfilaria in the skin and nodules in the Escuintla-Guatemala focus. Unpublished Ministry
of Public Health surveys from 1983 to 1991. Bars indicate the upper 95% confidence interval of the prevalence.
doi:10.1371/journal.pntd.0000404.g004
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